Clinical Trial Update: Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating high-dose vitamin D to sustain urticaria remission after discontinuation of omalizumab; the study has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urticaria

Drugs mentioned

• Cholecalciferol (Vitamin D3)
• Omalizumab (Omalizumab)

Snippet

Sponsor: Selina Gierer, D.O. | Conditions: Urticaria | Phase 4 | Status: WITHDRAWN